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The three mammalian Runx genes encode transcription 
factors that play essential but distinct and lineage-
specific roles in development.  These sequence-specific 
DNA binding proteins share a common binding cofactor 
(CBFβ) that confers protein stability and high affinity 
for target DNA on its RUNX partners. An important 
link to cancer was first realised through identification of 
both RUNX1 and CBFB as frequent targets for 
chromosomal translocations in human leukaemia.  Early 
studies suggested that RUNX1 is a tumour suppressor 
subject to dominant negative inhibition by its fusion 
oncoprotein derivatives and to loss-of-function 
mutations in AML (reviewed in [1]).  However, it is 
now clear that RUNX1 is far from a typical tumour 
suppressor as, for example, AML cells expressing the 
RUNX1-ETO fusion require the activity of the 
unaffected allele for survival [2] while ALL cases 
frequently over-express RUNX1 and/or display 
increased copy number [1]. Moreover, early studies on 
mouse models of lymphoma revealed all three Runx 
genes as targets for transcriptional activation in MYC 
transgenic mice, and the ability of over-expressed MYC 
and Runx to synergise in lymphoma has been amply 
confirmed in compound transgenics [1].   
Our recent study [3] sheds further light on the dualistic 
behaviour of the RUNX genes and validates their basal 
activities as potential targets for therapeutic 
intervention. By introducing a conditional knockout 
allele of Runx1 into the well-established Eμ-Myc model 
we showed that primary lymphoma cells strongly select 
for retention of both wild-type alleles while normal 
splenic lymphocytes can survive monoallelic deletion. 
Notably, normal myeloid cells are permissive for full 
deletion of Runx1, which may in part account for its 
preferential tumour suppressor activity in the myeloid 
lineage [1].  In contrast to primary Eμ-Myc lymphomas, 
established cell lines which have lost p53 survive 
complete deletion of Runx1.  However, deficiency is not 
without cost, as Runx1null cells proliferate more slowly 
and display increased sensitivity to the cytotoxic effects 
of glucocorticoids and DNA damage. Transcriptome 
analysis is consistent with this phenotype, as 
significantly altered probes were over-represented for 
genes controlling B-cell proliferation, survival and 
differentiation. Intriguingly, Rag1 and Rag2 were 
among   the   most  strongly   de-repressed   genes   after
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Runx1  deletion,  providing   a  mechanistic  rationale 
for the frequent occurrence of RAG-induced mutations 
in t(12;21) leukemias where TEL-RUNX1 compromises 
RUNX functions [4]. 
At first sight our findings contrast with a recent report 
that Runx1 deficiency in normal haematopoietic 
progenitors leads to reduced cell size due to down-
regulation of genes involved in ribosome biogenesis 
(Ribi). Moreover, Runx1 deficient progenitor cells 
displayed a stress-resistant, pro-survival phenotype that 
has been suggested as an explanation for susceptibility 
to transformation [5].  In contrast, we observed no 
change in cell size or Ribi gene expression in Eμ-Myc 
lymphomas after deletion of Runx1, and a marked 
increase in stress sensitivity [3]. An obvious difference 
between our studies is the presence of constitutively 
active Myc, a major driver of Ribi. It is conceivable that 
loss of signalling to Myc is the key to reduced cell size 
in Runx1null progenitors, notwithstanding the 
observation that Runx1 can bind directly at ribosomal 
gene loci [5].  However, another potential explanation 
that must be considered is that functional redundancy 
within the gene family rescues Runx1 deficient Eμ-Myc 
cells. These cells express low levels of Runx3, which is 
modestly increased in the absence of Runx1 [our 
unpublished observations).  It will be of great interest to 
explore the sensitivity of these cells to Runx3 
knockdown and to recently developed allosteric 
inhibitors of RUNX-CBFβ binding [6].   
While established Eμ-Myc lymphoma cells that express 
Runx1 have a clear selective advantage over excised 
cells, they are much less Runx-dependent than primary 
lymphomas in vivo.  This is very encouraging with 
regard to the prospects for treating primary lymphomas, 
which are more likely to have intact p53. Whether loss 
of p53 is sufficient to explain the ability of Eμ-Myc 
cells to survive without Runx1 is as yet unclear.  
However, this finding highlights another relevant 
feature of the potent collaboration between Runx and 
Myc which appears to suppress p53 function in 
lymphoma cells in vivo, providing a paradigm for 
collaborating oncogenes that act synergistically by 
neutralising the cell’s failsafe responses to oncogene 
over-activity [7].  One of the ‘grand challenges’ of 
contemporary cancer research is to find ways to target 
cancer cells over-expressing Myc. Inhibiting essential 
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oncogenic cofactors such as the Runx family offers one 
potential solution. If the mechanism by which Myc and 
Runx combine to disable p53 also proves to be 
mediated by druggable targets, this special relationship 
may have a further pay-off.   
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